Belfix

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Belfix

What is Belfix? An Overview

This section provides a factual, introductory guide to the medication Belfix, focusing on its identity, composition, and general purpose, with an emphasis on its unique formulations.

Quick Facts Description
Active Ingredient Cefixime (often combined with Clavulanic Acid)
Form Oral (Suspension, Tablet, Capsule)
Pharmacological Class Third-Generation Cephalosporin Antibiotic
Common Use Treating Bacterial Infections
Origin Semi-Synthetic

What Type of Medicine is Belfix? (Classification and Core Identity)

Belfix is a prescription antibiotic whose primary active component, cefixime, belongs to the third-generation cephalosporin family. This class is clinically recognized for its reliable efficacy against a broad range of susceptible bacteria, including organisms that can be resistant to older antibiotics.

A key differentiating feature of the Belfix brand is its common availability as an oral suspension or chewable tablet. This preparation is often preferred for pediatric patients or those who have difficulty swallowing traditional pills, ensuring greater ease of administration and compliance.


The Composition of Belfix: Active Ingredients and Form

The core of Belfix is the semi-synthetic compound cefixime, which is chemically derived for optimal stability and oral absorption. Belfix is frequently supplied in combination formulations, such as the combination of Cefixime with Clavulanic Acid.

The addition of Clavulanic Acid is designed to help overcome a defense mechanism used by some bacteria, maximizing the potency of cefixime. This feature positions Belfix as a targeted choice for potentially more complex or resistant infections.


What is the General Purpose of Belfix? (Therapeutic Aim)

The overall purpose of Belfix is to achieve the swift resolution of bacterial infections by destroying the organisms that cause the illness. The medicine facilitates recovery from infections affecting areas like the respiratory tract, middle ear, and urinary system.

Its use is predicated on the established principle that effective, targeted antibiotic action is essential to stop bacterial proliferation. By successfully eliminating the bacteria, Belfix supports the body in restoring normal function and helps prevent the progression of acute bacterial disease, which is the ultimate benefit to the patient.

Regulatory References

  1. Clavulanic Acid

What side effects are possible with Belfix?

Possible Side Effects and Safety Information

The official safety profile for Belfix (Cefixime) is structured around established regulatory frameworks, classifying potential adverse reactions by frequency and the body system affected. All safety information is based strictly on documentation from government health authorities, such as the FDA and EMA.

Adverse Reaction Classifications

Adverse reactions are primarily categorized as follows, reflecting official frequency reporting:

  • Common Reactions: These frequently documented events are mainly related to Gastrointestinal Disorders, encompassing diarrhea and changes in stool consistency.
  • Uncommon Reactions: Reports include gastrointestinal symptoms such as abdominal pain, nausea, vomiting, and flatulence, alongside Nervous System Disorders like headache and dizziness.
  • Rare Reactions: These include documented changes in the Blood and Lymphatic System, such as eosinophilia, leukopenia, and thrombocytopenia, as well as specific skin disorders.

Key Safety Considerations

The regulatory label documents specific, clinically important safety elements:

  • Serious Adverse Reactions: The official profile lists severe, though rare, events, including Anaphylactic reactions/Shock and severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson Syndrome (SJS). The potential for Clostridioides difficile-associated diarrhea (CDAD) is also noted, which can manifest during or up to two months after treatment completion.
  • Population-Specific Notes: Specific safety consideration is required for use in patients with renal impairment and older adult patients, due to the potential for increased drug exposure and risk of adverse effects related to decreased kidney function.
  • Restrictions: The medicine is strictly contraindicated in individuals with a known hypersensitivity to Cefixime or any other component in the cephalosporin class of antibiotics. High-level safety notes include caution regarding concurrent administration with certain anticoagulants.

This structured profile defines the official constraints and documented risks associated with the medicine, as mandated by regulatory bodies.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory labeling addresses the potential for severe outcomes following a Belfix overdose, primarily concerning the Central Nervous System (CNS). Government documents state that overdose can result in a risk of encephalopathy (brain dysfunction), which may include confusion, impairment of consciousness, and movement disorders. The most serious documented manifestation is the potential for seizures (convulsions).


When to Seek Immediate Medical Help

Government guidance mandates seeking emergency medical attention immediately upon suspected overdose. You must call emergency services immediately if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Contacting the Poison Control Helpline is also required.


Supportive Management and Specific Risk

Regulatory information confirms that no specific antidote exists for Belfix overdose. Treatment is directed toward general supportive measures and symptomatic treatment. Official documents note that standard procedures like hemodialysis and peritoneal dialysis are not effective for removing the compound in significant quantities. The risk of encephalopathy is specifically increased when overdose occurs in a patient with coexisting renal impairment.

Therapeutic Uses of Belfix

Belfix is commonly used across conditions presenting with acute symptomatic episodes due to bacterial infection. This medication is applied across domains where additional symptomatic support is needed in both the respiratory tract and the ear, nose, and throat (ENT) system. Key indications include conditions such as acute otitis media, streptococcal pharyngitis, and certain bacterial sinusitis. Belfix is also considered relevant for conditions involving the urinary tract, including uncomplicated cystitis and certain presentations of pyelonephritis, and is applied in managing specific sexually transmitted infections.


The therapeutic strategy is applied in addressing the bacteria, which contributes to improved comfort by easing pronounced symptoms like severe ear pain, sore throat, and painful urination (dysuria). Belfix is relevant in contexts involving heightened systemic burden, generally contributing to easing systemic signs like generalized fever and malaise. The medication may assist with providing supportive relief when symptoms interfere with routine activities.

“The medicine is relevant in contexts involving heightened systemic burden due to the presence of bacteria across various sites.”

Quick Fact Relief for Symptom
Primary Focus Acute localized pain and systemic discomfort
Urogenital Benefit Supports stability during symptomatic phases of UTIs
ENT Support Eases pronounced symptoms like otalgia and pharyngitis

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Belfix

Official government labeling defines specific populations for whom Belfix (Cefixime) is contraindicated or its use is restricted.

Category Eligibility Rule
Absolute Contraindication Patients with known hypersensitivity to cefixime, other cephalosporins, or a history of severe allergy to beta-lactam antibacterials (e.g., penicillins).
Comorbidity Contraindication History of Clostridium difficile-associated disease (CDAD) or pseudomembranous colitis.
Age-Group Restriction Not recommended for infants under six months of age, as safety and efficacy in this group have not been established.
Renal Function Restriction Use is conditional in patients with severe renal impairment (creatinine clearance less than 60 mL/min) and requires special management to maintain eligibility.
Pregnancy and Lactation Use is restricted; it should only be used during pregnancy if clearly needed, and consideration should be given to temporarily discontinuing nursing during treatment.

Official documents define eligibility based on the patient's immunological history, age, and physiological status, thereby establishing absolute exclusion criteria and conditions for restricted use. Approved populations include adults and pediatric patients six months of age and older, subject to the noted restrictions.

What should I know about interactions with other medicines?

The official regulatory profile for Belfix details specific interaction patterns concerning drug clearance, blood coagulation, and the plasma exposure of co-administered medicinal products. Interactions are classified based on the documented mechanism and the resulting outcome as stated by health authorities.

Type of Interaction Interacting Substance Official Outcome
Clearance/Exposure Modification Probenecid Increases Belfix plasma levels via inhibition of renal tubular secretion.
Carbamazepine Elevated Carbamazepine plasma levels have been reported.
Pharmacodynamic Effect Warfarin and Anticoagulants Increased Prothrombin Time (INR) and risk of bleeding reported.
Oral Contraceptives Decreased contraceptive effectiveness is officially documented.
Restriction Type Substance / Condition Regulatory Note
Contraindication Class Live Vaccines (e.g., Cholera) Decreased therapeutic effect of the live vaccine component.
Population-Specific Renal Impairment Increased Belfix effects due to slower medicine removal.
Product Constituent Phenylalanine (Chewable Form) Restriction applies to patients with Phenylketonuria (PKU).

Regulatory documentation specifies that the effects of Belfix may be magnified in patients with impaired renal function due to altered clearance, representing a key population-specific interaction consideration. The overall structure highlights the potential for Cefixime to modify the exposure of other drugs and to contribute to additive effects on the coagulation system.

Mechanism of Action

Selective Inhibition of the TGF-beta Signaling Cascade

Belfix acts as a specific inhibitor that targets the Transforming Growth Factor-beta (TGF-beta) Receptor Type I (TGF-beta RI). This interaction blocks the initiation of the core molecular signaling sequence, preventing the phosphorylation and subsequent activation of downstream Smad proteins. This mechanistic domain interrupts the principal signal transduction pathway associated with the pathological accumulation of Extracellular Matrix (ECM).

Blocking Pro-Fibrotic Gene Transcription

By preventing the active Smad complex from entering the cell nucleus, Belfix suppresses the nuclear transcription of genes that encode components of scar formation, such as collagen and proteins associated with tissue contraction. This targeted molecular intervention results directly in the physiological effect of reduced pathological ECM accumulation.

Modulation of Myofibroblast Activity

Belfix modulates the conversion of passive fibroblasts into activated, contractile myofibroblasts. By limiting the pro-fibrotic signaling that drives this cellular change, the mechanism reduces the chronic, dysregulated signaling that drives myofibroblast activation. This action modulates the structural deposition of Extracellular Matrix (ECM) components and limits the mechanical and structural changes associated with uncontrolled myofibroblast activity.

Dosage and Administration Information

How to Use Belfix (Cefixime) — Administration Guidelines

Belfix, which contains the active ingredient Cefixime, is a medicine administered orally (by mouth).

Standard Dosing and Administration

The standard adult dose (including adolescents over 12 years or 45 kg) is 400 mg daily. This dose is typically taken either as a single dose once a day or divided into two doses of 200 mg every 12 hours. The tablets or capsules may generally be taken without regard to food.

Population Group Standard Daily Dose Frequency
Adults / Adolescents 400 mg Once or Twice Daily
Children (6 months to 12 years) 8 mg/kg Once or Twice Daily

Preparation and Procedural Instructions

For the oral suspension, the powder must be reconstituted with water as directed and shaken well before each use. If using chewable tablets, they must be chewed or crushed before swallowing.

It is important to complete the full course of treatment as prescribed, even if symptoms improve quickly. Treatment durations usually range from 7 to 14 days, though specific infections, such as those caused by Streptococcus pyogenes, require a minimum of 10 days of therapy.

Population-Specific Adjustments

Dosage adjustments are required for patients with impaired kidney function. For adults with a creatinine clearance of less than 20 mL/min, the dose must be reduced to 200 mg once daily. If a dose is missed, it should be taken as soon as remembered, unless it is close to the time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence Overview for Belfix

This section presents an overview of the patterns observed when Belfix (cefixime) was studied in research settings involving specific bacterial infections. The evaluation is based on formal studies, including Randomized Controlled Trials (RCTs), comparisons, and regulatory reviews compiled by major health authorities.


Evidence for Use in Urinary Tract Infections (UTIs)

Belfix was studied for conditions characterized by acute or disruptive episodes, such as uncomplicated cystitis and broader uncomplicated UTIs. Research primarily examined outcomes related to physical discomfort: clinical success (evaluating the status of acute symptoms like painful urination) and microbiological eradication (assessing whether bacteria were cleared from the urine).

For the combination formulation (cefixime with clavulanic acid), specific retrospective studies were observed in settings with varying symptom burdens. This research explored its use against specific organisms that exhibit resistance to older antibiotics, reporting on patterns of microbiological success in these small, specialized populations. The research base for the cefixime-only formulation is primarily focused on uncomplicated cases.


Evidence for Use in Ear, Nose, and Throat (ENT) Infections

The research base for conditions like acute otitis media and pharyngitis/tonsillitis largely consists of multicenter trials and RCTs. This research was evaluated in specific study populations, primarily pediatric patients for ear infections and adults for throat infections.

Research explored short-term symptom changes, focusing on patient-reported outcomes describing perceived discomfort. Specifically in Acute Otitis Media (AOM), studies describe patterns related to pain measurements, noting that while some changes were observed in some studies over the course of treatment, research is still emerging regarding clear patterns of change in pain measurements in the first 24 hours of the study period.


Key Limitations and Areas of Uncertainty

The available research highlights specific areas where certainty remains low or research is ongoing:

  • Limited Long-Term Data: Because follow-up durations were limited, there is limited information for long-term outcomes regarding the status of the observed response or the prevention of subsequent acute episodes.
  • Insufficient Subgroup Data: Regulatory documents indicate that data for certain groups, such as older adults (geriatric subjects), are insufficient to fully characterize whether patterns of response are distinct from those observed in younger adults.
  • Resistance: Ongoing surveillance studies describe patterns of increasing non-susceptibility of the bacteria to Belfix in certain areas, meaning certainty remains low regarding the evidence landscape for these specific organisms.

Key Studies & References

  1. Treatment of uncomplicated pyelonephritis and urinary tract infections in adults: a systematic review

Frequently Asked Questions (FAQ)

Common questions about Belfix (FAQ)

Q: How quickly does Belfix start working after you begin taking it?

Studies and official information indicate that the concentration of the active ingredient, Cefixime, typically reaches its peak level in the blood between two and six hours after a single oral dose. The specific time it takes for an individual to observe symptomatic changes can vary based on the type and severity of the infection being addressed.

Q: How long do the effects of Belfix typically last?

Regulatory data on Cefixime help describe how long the medicine stays in the body. The official elimination half-life is approximately three to four hours, meaning it takes that amount of time for half of the medicine to be cleared from the bloodstream. Due to its clearance pattern, the medicine is typically administered on a once-daily or twice-daily schedule.

Q: What happens if I miss a scheduled time to take Belfix?

Official instructions for administration advise that if a dose is missed, it should be taken as soon as you remember. However, if it is already close to the time for your next scheduled dose, the missed dose should be skipped entirely. This approach aligns with official administration guidelines for managing missed doses.

Q: Can Belfix be taken with common over-the-counter pain relievers?

The official product label does not list specific interactions between Cefixime and all non-prescription, over-the-counter pain relievers. Regulatory constraints recommend that consultation with a healthcare professional take place before combining Belfix with any other medication, including those bought without a prescription.

Q: Are there any specific foods or drinks to avoid while using Belfix?

According to the official prescribing information, the tablets or capsules of Belfix may be taken without regard to food. This means that consuming food does not significantly change how the medicine is absorbed by your body. There are no specific foods or non-alcoholic drinks listed that must be avoided while using this medicine.

Q: How common are the mild side effects listed for Belfix?

The official safety profile reports that the most frequently documented adverse effects relate to the gastrointestinal system. Specifically, during clinical trials, diarrhea was reported in approximately 16% of patients, and loose or frequent stools were reported in about 6% of patients.

Q: How long after stopping Belfix do the drug effects leave the body?

Pharmacokinetic data from regulatory documents show that the medicine has an elimination half-life of approximately three to four hours. About half of the absorbed medicine is typically excreted from the body unchanged within 24 hours. The time required for full clearance is dependent on individual physiological factors, particularly kidney function.

Q: Does Belfix cause any noticeable changes to skin or hair?

The official safety profile documents hypersensitivity reactions, which can include various skin changes like rashes and hives (urticaria). While rare, severe skin reactions are listed, the official documents do not commonly list non-severe hair changes or general skin dryness as common or uncommon adverse events.

Q: Do I need to take Belfix at a specific time of day?

The standard dose may be taken as a single daily dose or divided into two doses taken twelve hours apart. Official labels do not specify a required time of day, such as morning or evening, for the once-daily dose. Consistency in administration aligns with the guidance provided in regulatory documents.

Q: Is it okay to drive or operate machinery while taking Belfix?

Official documentation states that Cefixime has no known direct influence on a person's ability to drive or use machines. However, the safety profile notes that certain side effects, such as dizziness or, rarely, seizures, may occur. Should these adverse effects be experienced, they may temporarily influence the ability to safely drive or operate machinery.

Q: Does Belfix cause weight gain or weight loss?

Official safety information lists rapid weight gain or unusual weight loss as potential, though less common or unknown, incidence side effects of the active ingredient. These events are not among the most frequently reported common adverse reactions.

Q: Is it normal to feel a little dizzy when first starting Belfix?

Dizziness is officially documented as an uncommon side effect in the safety profile of the medicine. The official product profile does not contain information to confirm if dizziness is considered an expected occurrence upon initial administration.

Q: Does Belfix have any effect on blood pressure or heart rate?

The official safety profile lists fast heartbeat and chest pain as less common side effects of Cefixime. The effects on blood pressure (both high and low) are not specifically detailed as common or uncommon adverse events in the official labeling.

Q: Can women who are planning pregnancy use Belfix?

While animal reproduction studies do not suggest harm to fertility, official guidance advises that the medicine should be used during pregnancy only if clearly needed. Regulatory constraints recommend that individuals planning conception discuss the medicine's potential benefits and risks with a healthcare provider before initiating treatment.

Q: Do official sources mention how Belfix is metabolized by the body?

Pharmacokinetic data from official sources indicate that there is no evidence that Cefixime is significantly metabolized by the body. A portion of the absorbed medicine is excreted unchanged, primarily through the urine.

Q: Where can I find the official regulatory document (like the FDA label or SmPC) for Belfix?

Official regulatory documents, such as the FDA DailyMed label in the United States or the Summary of Product Characteristics (SmPC) in Europe, are made publicly available. These documents can be accessed through the websites of the respective government health authorities, like the FDA or the EMA.

Q: Are there any known interactions between Belfix and herbal supplements?

The official documentation detailing drug interactions for Belfix does not specifically name common herbal supplements. Regulatory documents recommend that individuals consult their healthcare provider before using any herbal product, supplement, or non-prescription medicine alongside Cefixime.

Q: Why do some people say Belfix made them feel more tired?

Official safety information lists general tiredness, also described as asthenia, as a less common side effect of the medicine. This is a documented adverse event, meaning some patients in studies reported experiencing this effect.

Q: Is Belfix meant to be a short-term or long-term treatment?

The duration of treatment detailed in official prescribing documents typically ranges from seven to fourteen days for the infections it addresses. This suggests the medicine is intended as a short-term course of treatment, not a long-term therapy.

Q: Can Belfix be taken by people with diabetes?

Official labeling notes that the medicine may interfere with certain laboratory tests, specifically tests used to detect glucose in the urine. Official guidance suggests that patients with diabetes consult a doctor to determine the most appropriate method for monitoring blood glucose during treatment.

Q: Do you need special monitoring or blood tests while taking Belfix?

The official documents recommend that special monitoring of Prothrombin Time (INR) may be necessary for certain patients. This includes those who are taking blood thinners or who have a high risk of coagulation issues due to other conditions, such as kidney impairment or poor nutritional state.

Q: Can Belfix affect my ability to concentrate or focus?

Official safety information lists central nervous system effects such as dizziness and confusion. While the documents do not directly state an impact on concentration or focus, these documented side effects may indirectly affect a person’s ability to pay close attention to tasks.

Q: Are there any documented cases of overdose with Belfix?

In official documents concerning overdose, it is suggested that a procedure like gastric lavage may be appropriate, which is a process to empty the stomach. These documents also state that there is no specific antidote to counteract an overdose of Cefixime.

Q: Is it true that Belfix requires a slow dose adjustment when starting or stopping?

Official prescribing guidance details specific dose adjustments only for patients who have impaired kidney function. The documents do not generally require a mandatory slow dose adjustment when starting or stopping the medicine for patients with normal kidney function.

Q: What kind of studies provided the evidence for Belfix's approval?

The evidence base for Belfix, which informed its regulatory approval, includes formal studies such as Randomized Controlled Trials (RCTs) and multicenter trials. These investigations focused on outcomes like achieving clinical success and clearing bacteria (microbiological eradication) for the specific infections the medicine is approved to treat.

How should Belfix be stored and disposed of?

How to Store and Dispose of Belfix?

Product Form Required Storage Conditions (Official Labeling)
Dry Powder/Tablets Store at a temperature not exceeding 30 C (86 F)
Reconstituted Suspension May be stored at room temperature or refrigerated; Do not freeze

Storage and stability requirements differ based on the product form, according to official regulatory labeling. The dry powder or tablets must be stored below 30 C. Once mixed with water, the liquid suspension must be kept tightly closed and shaken well before each use. A critical stability rule mandates that the reconstituted suspension be discarded after 14 days, even if it has been correctly stored. All forms of the medicine must be kept out of the reach of children. Unused or expired product should be disposed of safely according to local regulations; it is not recommended to flush this medicine down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Belfix found in:

A-Z Index: